Back to News

Categories: News | Published On: June 12, 2024 | Written by webadmin@biolojic.com |

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

Back to News
More News
  • Biolojic Design Appoints Neal Curran as Chief Business Officer
    Read More
  • Biolojic Design Joins Johnson & Johnson Innovation – JLABS
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com